Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 <i>EGFR</i>-Mutant Non–Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study
PaperCitations, authors & open-access status
Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 <i>EGFR</i>-Mutant Non–Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 268 citations, 2019 year and closed oa status.
268
Citations
2019
Year
closed
OA Status